AstraZeneca (AZN -0.3%) starts to hear a growing chorus of investors and analysts calling for a...


AstraZeneca (AZN -0.3%) starts to hear a growing chorus of investors and analysts calling for a major shakeup of its board and management team amid a bit of a downward spiral. Bernstein Research's Jack Scannell thinks that instead of having marketing execs and attorneys running the show - the company should turn to either an Attila the Hun type of cost-slasher or a visionary scientist to right the ship.
From other sites
Comments (1)
  • jeffrey1947
    , contributor
    Comments (3) | Send Message
     
    To make a start get rid of the MD's and scientists who were promoted into senior managment positions through politics and who possess pitiful business skills and an even worse record of successful drug development and commercialization.
    9 Apr 2012, 05:39 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs